Prediction of therapeutic effects of human cardiomyocytes in myocardial infarction using non-human primates model

Cardiovascular disease (CVD) is a critical disease that accounts for 34% of all deaths and consumes almost $300 billion annually in the United States (1). Since myocardial infarction (MI) is the most severe and serious CVD with high lethality (2), attempts to overcome the disease are highly demanded. Although the development of pharmacological and intervention therapy enhances the survival rates, there are clear limitations to preventing or reversing the heart failure due to the massive muscle loss after MI.